Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LGVN Longeveron Inc

Pre-Market Trading 06-12 07:49:38 EDT

0.8200

-0.2400

-22.64%

盘前0.8800

+0.0600+7.32%

07:16 EDT

High1.15	Low0.7707	Vol1.47M
Open1.14	D1 Closing1.06	Amplitude35.78%
Mkt Cap5.21M	Tradable Cap3.53M	Total Shares6.35M
T/O1.47M	T/O Rate34.03%	Tradable Shares4.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":0.82,"timestamp":1718136000000,"preClose":1.06,"halted":0,"volume":1465261,"hourTrading":{"tag":"盘前","latestPrice":0.88,"preClose":0.82,"latestTime":"07:16 EDT","volume":5826,"amount":5249.9530847999995,"timestamp":1718191004114},"delay":0,"floatShares":4306400,"shares":6348624,"eps":-9.7892,"marketStatus":"Pre-Market Trading","change":-0.24,"latestTime":"06-12 07:49:38 EDT","open":1.14,"high":1.15,"low":0.7707,"amount":1465729.4439416998,"amplitude":0.35783,"askPrice":0.89,"askSize":1948,"bidPrice":0.88,"bidSize":19,"shortable":0,"etf":0,"ttmEps":-9.7892,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1718199000000},"marketStatusCode":1,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":0.82,"preHourTrading":{"tag":"盘前","latestPrice":0.88,"preClose":0.82,"latestTime":"07:16 EDT","volume":5826,"amount":5249.9530847999995,"timestamp":1718191004114},"postHourTrading":{"tag":"盘后","latestPrice":0.88,"preClose":0.82,"latestTime":"19:57 EDT","volume":19293,"amount":16731.8605,"timestamp":1718150247018},"volumeRatio":6.2961156619997265},"requestUrl":"/m/hq/s/LGVN/tweets","defaultTab":"tweets","newsList":[{"id":"2442396556","title":"Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2442396556","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442396556?lang=en_us&edition=fundamental","pubTime":"2024-06-11 21:00","pubTimestamp":1718110800,"startTime":"0","endTime":"0","summary":"With current HLHS treatment, only 50-60% of infants survive to adolescenceIn ELPIS I Phase 1 clinical trial, children experienced 100% transplant-free survival up to five years of age after receiving ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/11/2896885/0/en/Longeveron-Announces-Completion-of-Successful-Investigator-Meeting-for-On-going-Phase-2b-Clinical-Trial-Evaluating-Lomecel-B-as-a-Potential-Treatment-for-HLHS-a-Rare-Pediatric-Card.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","BK4139","BK4150","MSC","LGVN"],"gpt_icon":0},{"id":"2442836906","title":"Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2442836906","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442836906?lang=en_us&edition=fundamental","pubTime":"2024-06-11 19:00","pubTimestamp":1718103600,"startTime":"0","endTime":"0","summary":"MIAMI, June 11, 2024  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ldm8wneYHS9yfU2ej3bTbA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c4f5f7fb74321f8cf4d35709ef806d49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-72-110000675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","PSRHF","QID","ICUCW","LGMK","CIA","SUGCF","SQQQ","PSQ","QQQ","BK4139","ICU","BK4183","BK4082","LGVN","MHUA","INM","MNQmain","BK4198","RERE","BK4109","KASHF","BK4122","CLNNW","BK4023","TRGEF","BK4503","TQQQ","QLD","SNES","ATRA","PERF","CVKD","BK4007","BK4106","BK4097","FBRKF","NQmain","BK4149","UMAC",".IXIC","ASPI","AAWH","BIXT","BK4076","BK4162","CLNN","IMRN"],"gpt_icon":0},{"id":"2442841698","title":"Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2442841698","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442841698?lang=en_us&edition=fundamental","pubTime":"2024-06-10 21:00","pubTimestamp":1718024400,"startTime":"0","endTime":"0","summary":"MIAMI, June  10, 2024  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Eme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/10/2896042/0/en/Longeveron-to-Present-at-the-Emerging-Growth-Virtual-Conference-on-June-12-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4575","BK4150","LGVN","MSC"],"gpt_icon":0},{"id":"2440880494","title":"Longeveron Launches Contract Manufacturing Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2440880494","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440880494?lang=en_us&edition=fundamental","pubTime":"2024-06-03 22:57","pubTimestamp":1717426663,"startTime":"0","endTime":"0","summary":"Longeveron  said Monday that it launched its contract development and manufacturing business, with its first contract signed with Secretome Therapeutics. The company said its manufacturing services contract with Secretome will advance Secretome's portfolio of neonatal stem cell-based therapeutics. Financial details were not provided.Once fully operational, the contract manufacturing business can potentially generate $4 million to $5 million in annual revenue, the company said.Price: 1.03, Change: -0.07, Percent Change: -6.36","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2440849732","title":"Longeveron announces launch of contract development and manufacturing business","url":"https://stock-news.laohu8.com/highlight/detail?id=2440849732","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440849732?lang=en_us&edition=fundamental","pubTime":"2024-06-03 21:33","pubTimestamp":1717421590,"startTime":"0","endTime":"0","summary":"Longeveron  announced on Monday the launch of its contract development and manufacturing business at its 15,000 square feet Good Manufacturing Practice facility. According to LGVN, the facility contains 3,000 square feet of cleanroom space, including eight ISO 7 cleanrooms and ancillary areas, as well as 1,150 square feet of process development, quality control and warehousing space.  The company said it had initiated work under its first manufacturing services contract with Secretome Therapeutics Press Release","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4112329-longeveron-announces-launch-of-contract-development-and-manufacturing-business","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2440985054","title":"Longeveron® Announces Contract Development and Manufacturing Business and First Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2440985054","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440985054?lang=en_us&edition=fundamental","pubTime":"2024-06-03 21:00","pubTimestamp":1717419600,"startTime":"0","endTime":"0","summary":"Wa'el Hashad   Wa'el Hashad, CEO, Longeveron   Manufacturing facility 1   Longeveron GMP manufacturing facility  Contract manufacturing services as a new business line has the potential to generate ap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/03/2892283/0/en/Longeveron-Announces-Contract-Development-and-Manufacturing-Business-and-First-Contract.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","BK4575","BK4139","MSC","LGVN"],"gpt_icon":0},{"id":"2438731853","title":"Longeveron® to Attend BIO International Convention 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2438731853","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2438731853?lang=en_us&edition=fundamental","pubTime":"2024-05-28 20:05","pubTimestamp":1716897900,"startTime":"0","endTime":"0","summary":"MIAMI, May  28, 2024  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/28/2889001/0/en/Longeveron-to-Attend-BIO-International-Convention-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIO","BK4588","LGVN","BK4110","BK4585","AAIC","BK4139","BK4150","BK4575","BK4121","MSC"],"gpt_icon":0},{"id":"2436994221","title":"Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Longeveron (LGVN) and EDAP TMS (EDAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2436994221","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436994221?lang=en_us&edition=fundamental","pubTime":"2024-05-17 18:24","pubTimestamp":1715941485,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report), Lo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arvinas-holding-company-arvn-longeveron-lgvn-and-edap-tms-edap?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arvinas-holding-company-arvn-longeveron-lgvn-and-edap-tms-edap?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4139","BK4007","ARVN","EDAP","HCSG","BK4137","LGVN"],"gpt_icon":0},{"id":"2435326356","title":"Longeveron GAAP EPS of -$1.61 beats by $0.39, revenue of $0.55M beats by $0.49M","url":"https://stock-news.laohu8.com/highlight/detail?id=2435326356","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435326356?lang=en_us&edition=fundamental","pubTime":"2024-05-15 20:31","pubTimestamp":1715776308,"startTime":"0","endTime":"0","summary":"Longeveron press release  : Q1  GAAP EPS of -$1.61  beats by $0.39.Cash and cash equivalents and marketable securitiesas of March 31, 2024 were $2.3 million.The company believes its existing cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4106440-longeveron-gaap-eps-of--161-beats-by-039-revenue-of-055m-beats-by-049m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LGVN"],"gpt_icon":0},{"id":"2435654741","title":"LGVN Making Great Strides","url":"https://stock-news.laohu8.com/highlight/detail?id=2435654741","media":"Zacks Small Cap Research","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435654741?lang=en_us&edition=fundamental","pubTime":"2024-05-15 19:08","pubTimestamp":1715771280,"startTime":"0","endTime":"0","summary":"Longeveron  has been under the leadership of a new CEO for just over a year, and we continue to be impressed with Mr. Hashad’s decisions, vision, and focus. We have been telling investors about the great potential we’ve seen in early testing for the company’s signature treatment-Lomecel-B. However, as with many clinical-stage companies, we were concerned the company may be spreading its resources too thin. We understood that the multiple potential uses for Lomecel-B likely warranted multiple lines of testing but choosing that path can prove costly and has the potential to derail the company’s potential.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lgvn-making-great-strides-110800873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2434989143","title":"Longeveron Board Reshuffle and Nasdaq Compliance Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2434989143","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434989143?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:43","pubTimestamp":1715373836,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) has shared an announcement. Longeveron Inc. has experienced a shake-up in its Board of Directors with the immediate resignations ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-board-reshuffle-and-nasdaq-compliance-efforts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-board-reshuffle-and-nasdaq-compliance-efforts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","QID","SQQQ","LU2210149790.SGD","QLD","MNQmain","LGVN","LU2210150020.SGD","BK4139","BK4585","BK4588","NDAQ","PSQ","QQQ","LU2095319765.USD","BK4112","NQmain",".IXIC"],"gpt_icon":0},{"id":"2434899200","title":"Longeveron announces board transitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2434899200","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434899200?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:15","pubTimestamp":1715372105,"startTime":"0","endTime":"0","summary":"Longeveron  announced planned transitions on its Board of Directors. Richard Kender has joined the Longeveron Board of Directors. Roger Hajjar, former head of R&D at Ring Therapeutics, has been nominated as a candidate for the Board, subject to election at the Company’s Annual Meeting of Stockholders.  Neha Motwani, former managing director and senior healthcare investment banker at William Blair, Truist, and Oppenheimer and Company, also has been nominated as a candidate for the Board. Jeffrey Pfeffer and Cathy Ross have voluntarily resigned from the Board. Source: Press Release","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104825-longeveron-announces-board-transitions","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2434945896","title":"Longeveron Announces Board of Directors Planned Transitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2434945896","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434945896?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:05","pubTimestamp":1715342700,"startTime":"0","endTime":"0","summary":"Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron BoardDr. Roger Hajjar, former head of R&D at Ring Therapeutics, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/10/2879826/0/en/Longeveron-Announces-Board-of-Directors-Planned-Transitions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4575","BK4150","LGVN","MSC"],"gpt_icon":0},{"id":"2432722946","title":"Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432722946","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432722946?lang=en_us&edition=fundamental","pubTime":"2024-05-02 12:03","pubTimestamp":1714622580,"startTime":"0","endTime":"0","summary":"MIAMI, May  02, 2024  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/02/2874184/0/en/Longeveron-to-Report-First-Quarter-2024-Financial-Results-and-Host-Conference-Call-on-May-14-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4150","BK4139","BK4575","BK4585","LGVN","MSC","BK4218","HST","BK4588"],"gpt_icon":0},{"id":"2431857978","title":"Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV","url":"https://stock-news.laohu8.com/highlight/detail?id=2431857978","media":"ACCESSWIRE","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431857978?lang=en_us&edition=fundamental","pubTime":"2024-04-29 21:00","pubTimestamp":1714395600,"startTime":"0","endTime":"0","summary":"LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las Vegas, NV.The Planet MicroCap Showcase begins on Tuesday, April 30, 2024 with the \"MicroCap Investing Workshop\" starting at 12:00pm PST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders, followed by 96 MicroCap public and private company presentations on Wednesday, May 1, 2024, and 1x1 meetings on Thursday, May 2, 2024.On Wednesday, May 1, 2024, the following issuers will be presenting their companies. Below are the webcasting links to view those presentations if you can't attend the showcase live.Altigen Communications - \"Top Tier Track\" Q&A with Maj Soueidan, GeoInvesting.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keynotes-educational-panels-96-companies-130000391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPGC","PERF","ATOS","HGBL","NXGL","GLXZ","COCH","RAIL","ACHV","APCX","HWAIF","CREX","QPRC","BSEM","DLPN","FTHM","BYRN","LGVN","FWBI","NXGLW","NAOV","TRUG","CYCA","UGEIF","YERBF","SABOF","BENF","SSKN","DDOSF","ADMQ","INXSF","ALCO","GREE","DMGGF","NEPH","PRPH","TNXP","GLGI","LUXHP","PAPL","XXII","TGCB","VOXR","LAKE","LUXH","MTC","CING","VCIG","CXDO","LRHC","WISA","XELB","RELL","ACON","DCMDF","SHPH"],"gpt_icon":0},{"id":"2431403835","title":"Analysts’ Top Healthcare Picks: Longeveron (LGVN), Optinose (OPTN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2431403835","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431403835?lang=en_us&edition=fundamental","pubTime":"2024-04-29 18:20","pubTimestamp":1714386019,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Longeveron (LGVN – Research Report), Optinose (OPTN ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-longeveron-lgvn-optinose-optn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-longeveron-lgvn-optinose-optn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","BK4007","BK4137","HCSG","BK4139","OPTN"],"gpt_icon":0},{"id":"2430259688","title":"Longeveron to Present at the Planet MicroCap Showcase","url":"https://stock-news.laohu8.com/highlight/detail?id=2430259688","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2430259688?lang=en_us&edition=fundamental","pubTime":"2024-04-25 20:05","pubTimestamp":1714046700,"startTime":"0","endTime":"0","summary":"MIAMI, April  25, 2024  (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Pl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/25/2870051/0/en/Longeveron-to-Present-at-the-Planet-MicroCap-Showcase.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","BK4575","BK4139","MSC","LGVN"],"gpt_icon":0},{"id":"2428001665","title":"BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Closes on Multimillion-Dollar Warrant Exercise Offering, Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2428001665","media":"StreetInsider","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428001665?lang=en_us&edition=fundamental","pubTime":"2024-04-19 23:40","pubTimestamp":1713541200,"startTime":"0","endTime":"0","summary":"Longeveron , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome , Alzheimer’s disease and Aging-Related Frailty, has closed on its warrant exercise offering. According to the announcement, the exercise comprised certain existing warrants to purchase 2,399,744 shares of LGVN Class A common stock; the warrants were originally issued in October 2023 and April 2024. The proceeds from the warrant exercise offering will be combined with a public offering, which closed earlier this month; together the two transactions resulted in approximately $11.4 million before the deduction of placement agent fees and standard offering expenses. The company anticipates using funds from the offerings to support the ongoing clinical and regulatory development of Lomecel-B for the treatment of several disease states and indications, including HLHS and Alzheimer’s disease; funds may also be used","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23089353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["TM","03160","BK4099","BK4588","TQQQ","LGVN","PSQ","NDAQ","BK4112","SQQQ",".IXIC","QID","NQmain","BK4585","BK4139","LU2210149790.SGD","LU2095319765.USD","QQQ","QLD","BK4555","LU2210150020.SGD","MNQmain"],"gpt_icon":0},{"id":"2428285547","title":"Longeveron Bolsters Market Position with Strategic Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2428285547","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428285547?lang=en_us&edition=fundamental","pubTime":"2024-04-19 04:43","pubTimestamp":1713473014,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) has shared an update. Longeveron Inc., a biotech firm, has engaged in financial maneuvers to strengthen its position in the marke...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-bolsters-market-position-with-strategic-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-bolsters-market-position-with-strategic-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":-0.2115},{"period":"1month","weight":-0.4364},{"period":"3month","weight":-0.826},{"period":"6month","weight":-0.9604},{"period":"1year","weight":-0.9785},{"period":"ytd","weight":-0.9397}],"compareEarnings":[{"period":"1week","weight":0.0162},{"period":"1month","weight":0.0309},{"period":"3month","weight":0.0407},{"period":"6month","weight":0.1376},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.1297}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.243376},{"month":2,"riseRate":0,"avgChangeRate":-0.072728},{"month":3,"riseRate":0.25,"avgChangeRate":0.054898},{"month":4,"riseRate":0.25,"avgChangeRate":-0.183032},{"month":5,"riseRate":0.5,"avgChangeRate":-0.110991},{"month":6,"riseRate":0.5,"avgChangeRate":-0.038752},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.088032},{"month":8,"riseRate":0,"avgChangeRate":-0.27},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.126547},{"month":10,"riseRate":0,"avgChangeRate":-0.067469},{"month":11,"riseRate":0.666667,"avgChangeRate":2.226115},{"month":12,"riseRate":0,"avgChangeRate":-0.338864}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction